Notable life science industry activity for this coverage week: FDA approvals, clinical trial milestones, funding rounds, grants, and deals. Pulled from public industry data, not personalized to any one company or account.
There's a quiet shift happening in how difficult diseases get treated and diagnosed. This week brought a cluster of approvals and funding decisions that point the same direction: the companies doing the specialized work of manufacturing, testing, and running trials are getting busier.
Novartis won European approval for Itvisma, a gene therapy for spinal muscular atrophy, a rare genetic disease caused by a fault in the SMN1 gene that shows up in children and adults. Gene therapies are made from living cells and are fiddly to manufacture, so an approval like this tends to pull in the specialist manufacturers who handle that kind of work. At the same time, Elicio Therapeutics raised $15 million to move into Phase 1 testing, the earliest stage of human trials, for ELI-002 7P in metastatic pancreatic cancer, a hard-to-treat form of the disease. That kind of capital flowing into early-stage oncology work signals continued investor appetite for novel approaches in cancers that have few good options.
Medicare agreed to pay for NASHnext, a blood test from GENFIT that spots metabolic dysfunction-associated steatohepatitis, a common fatty liver disease that used to require a needle biopsy to diagnose. A blood draw is easier, but the real unlock is coverage. Tests like this tend to sit unused until someone agrees to reimburse them, so it's the reimbursement decision, not the test itself, that puts it in a doctor's hands. Roche, meanwhile, announced that divarasib beat two approved drugs aimed at a specific genetic fault in lung cancer when compared directly against them in a Phase III trial, showing meaningful improvements in how long patients survived. Competitive trial outcomes like that reshape which drugs doctors reach for and which manufacturers get pulled into production.
We only see what we happen to pick up, so treat this as a few signals, not the whole board. But if you're in the middle of the chain, running trials or making the harder therapies, it was a week worth noticing.